- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00464789
Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Healthy Postmenopausal Women
December 19, 2007 updated by: Wyeth is now a wholly owned subsidiary of Pfizer
An Open-Label, Single-Dose, Randomized, 3-Period, Crossover, Bioequivalence Study Between Bazedoxifene/Conjugated Estrogens (Premarin Current Process) And Bazedoxifene/Conjugated Estrogens (Premarin New Process) In Healthy Postmenopausal Women
Bazedoxifene/Conjugated Estrogens (BZA/CE) is an investigational drug that is being developed for treatment of menopause.
The purpose of this trial is to compare a new manufacturing process for making BZA/CE to the current process by assessing the way it is absorbed into the blood.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
35 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Postmenopausal women aged 35 to 70 years
- Body mass index (BMI) in the range of 18.0 to 35.0 kg/m2 and body weight greater than or equal to 50 kg
- Healthy as determined by the investigator on the basis of medical history, physical examination, breast and gynecologic examination, clinical laboratory test results, vital signs, and 12-lead electrocardiogram (ECG).
Exclusion Criteria:
- Any clinically important active condition of gynecologic, cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease.
- History or current evidence of thrombophlebitis, thromboembolic disorders, or any coagulopathies.
- History of any clinically important drug allergy to conjugated estrogens (CE) or selective estrogen receptor modulators (SERMs).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
PK results
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2007
Study Completion (Actual)
May 1, 2007
Study Registration Dates
First Submitted
April 23, 2007
First Submitted That Met QC Criteria
April 23, 2007
First Posted (Estimate)
April 24, 2007
Study Record Updates
Last Update Posted (Estimate)
December 28, 2007
Last Update Submitted That Met QC Criteria
December 19, 2007
Last Verified
December 1, 2007
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 3115A1-1120
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Menopause
-
Riphah International UniversityCompleted
-
Englewood Hospital and Medical CenterNanohealth, Inc.WithdrawnMenopause SymptomsUnited States
-
Englewood Hospital and Medical CenterNanohealth, Inc.CompletedMenopause SymptomsUnited States
-
University of Colorado, DenverCompletedMenopause | Pre-menopauseUnited States
-
S.LAB (SOLOWAYS)Center of New Medical TechnologiesCompletedMenopause SymptomsRussian Federation
-
BHR Pharma, LLCTerminatedMenopause Related ConditionsGermany
-
Singapore General HospitalRecruitingMenopause | Menopause Related ConditionsSingapore
-
University of ArkansasRecruitingMenopause Related ConditionsUnited States
-
Wake Forest University Health SciencesWithdrawnMenopause Related Conditions
-
I.M. Sechenov First Moscow State Medical UniversityCompletedMenopause Related ConditionsRussian Federation
Clinical Trials on Bazedoxifene/Conjugated Estrogens 20 mg/0.625 mg tablet
-
PfizerCompletedMenopause | OsteoporosisUnited States, Colombia, Australia, Hungary, Poland, Finland, Argentina, Chile, Denmark, Mexico, New Zealand, Norway
-
Wyeth is now a wholly owned subsidiary of PfizerTerminated
-
Carol Fabian, MDBreast Cancer Research FoundationTerminatedFocus of Study is Healthy Women at Risk for Breast CancerUnited States
-
University of Southern CaliforniaNational Institute on Aging (NIA)RecruitingAtherosclerosis | Cognitive DeclineUnited States
-
Instituto Nacional de Ciencias Medicas y Nutricion...Completed
-
Loyola UniversityCompletedOveractive BladderUnited States
-
PfizerCompletedEndometrial Hyperplasia | OsteoporosisUnited States
-
Wyeth is now a wholly owned subsidiary of PfizerCompleted
-
Wake Forest University Health SciencesNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
Laval UniversityV Joseph; C Minville; C RheaumeRecruitingSleep Apnea | Oxidative Stress | Post MenopausalCanada